Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of GuidancePRNewsWire • Wednesday
Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect?Zacks Investment Research • Monday
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4PRNewsWire • 10/28/26
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowZacks Investment Research • 10/05/26
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeZacks Investment Research • 10/02/26
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research • 09/30/26
Precigen: The FDA's Platform Technology Designation And The Institutional Crossover EffectSeeking Alpha • 09/30/26
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?Zacks Investment Research • 09/14/26
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and PrecigenZacks Investment Research • 08/27/26
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven CancersAccesswire • 08/25/26
Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great ChoiceZacks Investment Research • 08/14/26
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 AdvancementSeeking Alpha • 08/06/26